Among the type A preparations, are Onabotulinum toxin A or Botox (Allergan, Inc., Irvine, CA) and Abobotulinum toxin A or Dysport (Ipsen Limited, Slough, Berkshire, UK) which are not bioequivalent. ![]() Īlthough the human nervous system is affected by all seven types (A–F), if applied parentally, type A preparations are most commonly used in clinical practice for various reasons such as their prior availability, immunologic aspects, safety, and efficacy. It has been well studied in neurology as well as other disciplines, as focal hyperhidrosis, axillary, and PHH and is considered the treatment of choice in many of its indications. īotulinum toxin is a potent neurotoxin which specifically inhibits the release of acetylcholine from nerve terminals by acting mainly on the cholinergic synapses. The condition causes significant disruption in both social and professional life, leading to a marked impact on the patient’s quality of life (QOL). Palmar hyperhidrosis (PHH) is a condition characterized by excessive sweating of the palms. There was a trend towards a more rapid action after Dysport treatment but without significant importance. The efficacy and safety of Botox and Dysport injections were similar using a conversion factor of 1 : 2.5. Patients with longer disease duration were more liable to relapse. Continued evaluation showed similar improvement in both palms with a nonsignificant difference. At 8 weeks, this difference turned insignificant. At 3 weeks, a significant decrease in sweating for both preparations was noted which was more pronounced with Dysport compared with Botox. ![]() Clinical assessment was performed at baseline and posttreatment for 8 months using Minor’s iodine starch test, Hyperhidrosis Disease Severity Scale (HDSS), and Dermatology Life Quality Index (DLQI) test. Eight patients with severe PPH received intradermal injections of Botox in one palm and Dysport in the other in the same session. This paper aims to compare the efficacy of Botox and Dysport in PPH using a conversion factor of 1 : 2.5. Results regarding an appropriate conversion factor between them are controversial. Two preparations of botulinum A toxin (BTX-A) are commercially available for the treatment of palmar hyperhidrosis (PPH): Botox (Allergan 100 U/vial) and Dysport (Ipsen Limited 500 U/vial), which are not bioequivalent.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |